I+ Solutions,

I+ Solutions is a pharmaceutical importer and buyer based in Mozambique, specializing in the procurement of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in Mozambique's healthcare sector by ensuring the availability of essential medications, particularly in the treatment of tuberculosis and other infectious diseases. While specific details about its headquarters, parent company, and organizational structure are not publicly disclosed, I+ Solutions is recognized for its significant contributions to the pharmaceutical distribution network within the country.

I+ Solutions operates a centralized distribution model, importing pharmaceutical products primarily from India. The company manages a warehouse facility in Maputo, the capital city of Mozambique, which serves as the main hub for storage and distribution. This strategic location enables efficient logistics and timely delivery of medications to various healthcare providers across the country. While the company focuses on domestic distribution, there is no publicly available information indicating operations beyond Mozambique's borders.

In Mozambique's pharmaceutical supply chain, I+ Solutions functions as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company ensures a steady supply of essential medications to the domestic market. Its focus on importing finished products, rather than raw active pharmaceutical ingredients (APIs), underscores its role in facilitating the availability of ready-to-use medicines for healthcare providers and patients throughout Mozambique.

I+ Solutions demonstrates a high degree of supplier concentration, sourcing all its pharmaceutical imports from a single supplier: Aurigene Pharmaceutical Services Limited. This exclusive sourcing strategy indicates a deep, strategic partnership between I+ Solutions and Aurigene, potentially leading to favorable terms and consistent product quality. However, this single-source dependency also poses risks, such as supply chain disruptions in the event of issues with the supplier. The stability of this relationship is crucial for I+ Solutions' operations, and any changes in the supplier's circumstances could significantly impact the company's ability to meet domestic pharmaceutical demand.

The resilience of I+ Solutions' supply chain is closely tied to its exclusive relationship with Aurigene Pharmaceutical Services Limited. While this partnership may offer benefits like streamlined procurement processes and assured product quality, it also exposes the company to risks associated with single-source dependency. The lack of publicly available information about backup suppliers or alternative sourcing strategies suggests limited diversification in I+ Solutions' supply chain. This concentration could be a strategic choice to maintain close control over product quality and supply consistency. However, it also means that any disruptions affecting Aurigene could have a significant impact on I+ Solutions' ability to supply the Mozambican market.

I+ Solutions' sourcing pattern, characterized by exclusive procurement from a single supplier, positions the company to benefit from strong supplier relationships and potentially favorable terms. This strategy may enhance operational efficiency and product consistency. However, the high supplier concentration also introduces vulnerabilities, particularly in the face of supply chain disruptions or changes in the supplier's operational status. For Indian exporters seeking to become alternative suppliers to I+ Solutions, this presents an opportunity to diversify the company's supply base. Offering competitive pricing, reliable delivery schedules, and high-quality products could attract I+ Solutions as a new customer, thereby reducing its dependency on a single supplier and enhancing supply chain resilience.

The regulation of pharmaceutical products in Mozambique is governed by Law No. 12/2017 of 8th September, which establishes the rules applicable to the production, distribution, use, and marketing of medicines, vaccines, biological products, and health products. This legislation provides a comprehensive framework for ensuring the safety, efficacy, and quality of pharmaceutical products within the country. The Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME) is the national regulatory authority responsible for overseeing the pharmaceutical sector, including the registration and monitoring of pharmaceutical products. ANARME's role is crucial in maintaining the integrity of the pharmaceutical supply chain and protecting public health in Mozambique.

Importers of pharmaceutical products in Mozambique must obtain a license from the Ministry of Industry and Commerce. The licensing process requires compliance with specific conditions, including the recruitment of a qualified technical manager with the necessary qualifications and professional profile approved by the Ministry of Health. Applicants must also demonstrate exclusive dedication to the importation of pharmaceutical products and possess a warehouse that meets safety, security, and storage requirements for medicines. Additionally, importers are required to provide a plan of the establishment, including descriptions and sizes of the areas, and undergo a pre-inspection conducted by the Department of Pharmacy (DoP), which submits an opinion to the Minister of Health. There is a fee payable for a license to export permit of medicines, vaccines, biological, and other health products to importers per the guidelines set forth by the Ministry of Industry and Commerce. (apiex.gov.mz)

Pharmaceutical products imported into Mozambique must comply with specific quality and labeling requirements. Batch testing and stability studies are mandatory to ensure the safety and efficacy of the medicines. Labeling must be in Portuguese, the official language of Mozambique, and should include all necessary information as stipulated by ANARME. Serialization mandates may also apply to enhance traceability and prevent counterfeit products from entering the market. These regulations are designed to protect public health by ensuring that all pharmaceutical products meet the required standards of quality and safety.

Between 2024 and 2026, Mozambique has implemented several regulatory changes affecting pharmaceutical imports. In May 2025, the government approved Resolution No. 18/2025, which establishes the Regulation on the Legal Framework for the Licensing of Establishments for the Sale of Pharmaceutical Products at Retail. This regulation repeals previous decrees and introduces new requirements for the licensing of pharmacies and pharmaceutical sales outlets, including compliance with infrastructure, equipment, and technical management standards. The regulation also classifies establishments based on the type of service they provide, with pharmacies being categorized as type "A," "B," or "C." These changes aim to strengthen the regulatory framework and improve the quality of pharmaceutical services in Mozambique.

I+ Solutions' product strategy focuses on importing finished pharmaceutical formulations, particularly in the therapeutic areas of tuberculosis medications, advanced antibiotics, and antiviral & HIV medications. This focus aligns with the high demand for these treatments in Mozambique, where infectious diseases are prevalent. The company's import portfolio is heavily concentrated, with the top five products accounting for 91.8% of total imports. This concentration indicates a strategic emphasis on key therapeutic areas to address the most pressing health challenges in the country.

I+ Solutions employs a sourcing strategy that relies exclusively on a single supplier, Aurigene Pharmaceutical Services Limited, for its pharmaceutical imports. This approach suggests a preference for strong, long-term supplier relationships to ensure product quality and supply consistency. The company's focus on finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a strategy aimed at providing ready-to-use medicines to the Mozambican market. While this sourcing model offers benefits such as streamlined procurement processes, it also introduces risks associated with single-source dependency.

Based on its product mix, I+ Solutions primarily serves the wholesale distribution segment of the Mozambican pharmaceutical market. By importing and distributing finished pharmaceutical formulations, the company supplies essential medications to various healthcare providers, including public hospitals, private clinics, and retail pharmacies. Its focus on high-demand therapeutic areas positions I+ Solutions as a key player in addressing the country's healthcare needs, particularly in the treatment of infectious diseases.

There is a realistic opportunity for new Indian suppliers to enter I+ Solutions' supply chain. The company's exclusive sourcing from a single supplier presents an opportunity to diversify its supplier base, thereby enhancing supply chain resilience. Indian exporters can leverage this opportunity by offering competitive pricing, reliable delivery schedules, and high-quality products. By meeting these criteria, new suppliers can position themselves as viable alternatives to I+ Solutions' current supplier, potentially capturing a share of the company's import volume.

Indian exporters seeking to supply I+ Solutions and the broader Mozambican market must adhere to specific certifications, quality standards, and regulatory approvals. Products must be registered with ANARME, Mozambique's national regulatory authority, which requires comprehensive documentation covering quality, safety, efficacy, stability, and manufacturing compliance, including WHO-GMP certification. Additionally, importers must obtain a license from the Ministry of Industry and Commerce, which involves compliance with specific conditions, including the recruitment of a qualified technical manager and possession of a compliant warehouse facility. (apiex.gov.mz)

To establish a relationship with I+ Solutions, Indian exporters should first ensure that their products are registered with ANARME and meet all regulatory requirements for importation into Mozambique. Engaging in direct communication with I+ Solutions to understand their specific procurement needs and quality expectations is crucial. Participating in relevant tenders and trade events can also provide opportunities to